logo
Boston Children's nurse completes virtual Pan-Mass Challenge after missing race for stem cell donation

Boston Children's nurse completes virtual Pan-Mass Challenge after missing race for stem cell donation

CBS News2 days ago
A Boston Children's Hospital nurse wasn't expecting to be in a hospital bed when she was meant to be riding in the Pan-Mass Challenge, but she was grateful it was for a life-changing reason: stem cell donation.
Kristin McIntire is no stranger to long rides. The Boston nurse has completed 10 marathons and several 100-mile bike races.
"I love exercise. I love being active," she said, jokingly adding that she commutes to work on her bike. "I don't know if you're familiar with Boston traffic, but it's certainly the most easy way to get around."
But for McIntire, riding has always been about more than just fitness. It's personal and it's purposeful.
"I've always needed to align that with a higher purpose, that I don't feel like I'm doing it by myself. So whether that's riding with a team, running with a team fundraising for a group, it's been a lot more meaningful for me," McIntire said.
For years, McIntire served as a pediatric oncology nurse at Boston Children's Hospital, working on one of the most intense and emotional floors in the building.
"There are other outcomes that aren't so great... where the family is leaving without their child," she recalled. "And that's really, really sad."
She rides in the Pan-Mass Challenge with Pedal for Pediatrics, a team made up of coworkers that raises money for children and families facing cancer at Dana-Farber and Boston Children's.
But last year, just as she was preparing for the big ride, Kristin received a life-changing message: she'd been matched as a stem cell donor.
"It was honestly so crazy. I was like, wait, what?" McIntire said.
She spent what would've been Pan-Mass Challenge weekend in a hospital bed in Florida, donating stem cells to a stranger with leukemia.
"That was a pretty cool reason to stop training, I would say," McIntire said.
Though she couldn't be on the course, McIntire found another way to finish the journey. In the weeks after her donation, she completed multiple 50-mile rides virtually.
"This team directly provides funding that benefits those patients directly, whether that's ride share services or meal coupons, anything that can help support this family," McIntire said.
McIntire has never met the person she helped. She doesn't even know their name. But she knows they're still alive.
"I saved a person's life, and I was a little tired after the donation, and that was it," McIntire said.
"Whether you're riding, whether you're volunteering, or whether you're out there cheering— all of that matters, and it's very important work," she added.
McIntire's stem cell procedure was not a traditional bone marrow surgery.
Most donations today are done through a simple outpatient blood draw called peripheral blood stem cell donation.
You can learn more or join the registry here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Boston Children's nurse completes virtual Pan-Mass Challenge after missing race for stem cell donation
Boston Children's nurse completes virtual Pan-Mass Challenge after missing race for stem cell donation

CBS News

time2 days ago

  • CBS News

Boston Children's nurse completes virtual Pan-Mass Challenge after missing race for stem cell donation

A Boston Children's Hospital nurse wasn't expecting to be in a hospital bed when she was meant to be riding in the Pan-Mass Challenge, but she was grateful it was for a life-changing reason: stem cell donation. Kristin McIntire is no stranger to long rides. The Boston nurse has completed 10 marathons and several 100-mile bike races. "I love exercise. I love being active," she said, jokingly adding that she commutes to work on her bike. "I don't know if you're familiar with Boston traffic, but it's certainly the most easy way to get around." But for McIntire, riding has always been about more than just fitness. It's personal and it's purposeful. "I've always needed to align that with a higher purpose, that I don't feel like I'm doing it by myself. So whether that's riding with a team, running with a team fundraising for a group, it's been a lot more meaningful for me," McIntire said. For years, McIntire served as a pediatric oncology nurse at Boston Children's Hospital, working on one of the most intense and emotional floors in the building. "There are other outcomes that aren't so great... where the family is leaving without their child," she recalled. "And that's really, really sad." She rides in the Pan-Mass Challenge with Pedal for Pediatrics, a team made up of coworkers that raises money for children and families facing cancer at Dana-Farber and Boston Children's. But last year, just as she was preparing for the big ride, Kristin received a life-changing message: she'd been matched as a stem cell donor. "It was honestly so crazy. I was like, wait, what?" McIntire said. She spent what would've been Pan-Mass Challenge weekend in a hospital bed in Florida, donating stem cells to a stranger with leukemia. "That was a pretty cool reason to stop training, I would say," McIntire said. Though she couldn't be on the course, McIntire found another way to finish the journey. In the weeks after her donation, she completed multiple 50-mile rides virtually. "This team directly provides funding that benefits those patients directly, whether that's ride share services or meal coupons, anything that can help support this family," McIntire said. McIntire has never met the person she helped. She doesn't even know their name. But she knows they're still alive. "I saved a person's life, and I was a little tired after the donation, and that was it," McIntire said. "Whether you're riding, whether you're volunteering, or whether you're out there cheering— all of that matters, and it's very important work," she added. McIntire's stem cell procedure was not a traditional bone marrow surgery. Most donations today are done through a simple outpatient blood draw called peripheral blood stem cell donation. You can learn more or join the registry here.

Breakthrough Innovations Transforming Lung Cancer Diagnosis and Treatment
Breakthrough Innovations Transforming Lung Cancer Diagnosis and Treatment

Time Business News

time7 days ago

  • Time Business News

Breakthrough Innovations Transforming Lung Cancer Diagnosis and Treatment

Lung cancer is a type of cancer that begins in the lungs, often caused by smoking, exposure to pollutants, genetic factors or commercial threats. Lung cancer market is increasing due to growing global lung cancer rate, awareness and increase in screening programs, progress in clinical technologies (such as low -dosage CT scans and liquid biopsy) and increasing remedies and development of targeted remedies and immunotherapy. Additionally, better healthcare in aging population and emerging areas is promoting infrastructure and early detection and demand for effective treatment solutions. Key Growth Drivers and Opportunities Growing Global Lung Cancer Rate: Rising global lung cancer rate is a major driver of lung cancer market development, as it increases the demand for early identity, accurate diagnosis and effective treatment solutions. One of the major causes of cancer-related deaths worldwide with lung cancer, healthcare systems are making heavy investments in advanced screening tools such as low-dosage CT scans and biomarker-based diagnosis to enable the first diagnosis. At the same time, rising patient numbers are accelerating the development and adoption of innovative remedies including targeted drugs and immunotherapy. The burden of growing disease also attracts more research funds and industry investment, further fuel to market expansion. Challenges The lung cancer market faces several borders, including advanced diagnosis and high cost of targeted treatments, which can limit access to areas with especially low and moderate income. Delayed diagnosis also disrupts the results of treatment due to lack of awareness, limited screening programs and non-specific initial symptoms. Additionally, the challenge of complex regulatory routes, delayed stage patients, and the challenge of managing side effects from therapy disrupts the market growth despite technological progress. Innovation and Expansion EQUAL Study Launches High-Risk Group Lung Cancer Screening Trial In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco. Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate. With India's First LungLife Screening Program to Fight Lung Cancer, Apollo Cancer Centre Sets the Standard In March 2025, India's first LungLife Screening Program for early lung cancer diagnosis has been introduced by Apollo Cancer Centres (ACCs), a pioneer in state-of-the-art cancer care. Lung cancer, which makes up 5.9% of all malignancies and 8.1% of cancer-related deaths in India, is the target of this ground-breaking project. Early identification increases the survival rate and improves treatment results (LINK). Low-dose computed tomography (LDCT) early screening can greatly increase survival chances and help with early diagnosis. However, almost 80% of high-risk patients have never spoken to their doctors about screening. To allow early detection and save lives, it is imperative to improve knowledge and communication regarding lung cancer screening, particularly among high-risk individuals. Inventive Sparks, Expanding Markets The key players operating the lung cancer market include AstraZeneca, Hoffman La Roche, Eli Lilly and Company, Pfizer Inc., Merck & Co., Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb Company. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

Yahoo

time7 days ago

  • Yahoo

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store